DIRUI(SZ:300396)2022-12-06 10:50Financial Performance - In the first half of the year, the company achieved operating revenue of 335 million CNY, a year-on-year increase of 48.08% [3] - Operating profit reached 78.57 million CNY, up 78.43% compared to the same period last year [3] - Net profit attributable to shareholders was 62.45 million CNY, reflecting a growth of 30.03% year-on-year [3] - The company's subsidiary, Ningbo Ruiyuan, reported operating revenue of 88.34 million CNY and net profit of 31.60 million CNY [3] Revenue Breakdown - Instrument revenue accounted for 135 million CNY, while test paper products generated 36 million CNY and reagent revenue was 164 million CNY [3] - Domestic revenue was 265 million CNY, showing a growth of 55.29%, while international revenue approached 70 million CNY, increasing by 25.71% [3] Product Development - As of June 2016, the company had 51 chemical luminescence reagent products in the approval stage [4] - The CM-240 fully automated chemical luminescence analyzer has received registration certification from the Jilin Provincial Food and Drug Administration [4] Strategic Direction - The company aims to enhance governance structure, improve management efficiency, and increase profitability to maximize investor value [3] - Future plans include expanding into new business areas through acquisitions and mergers [3] Sales Strategy - The sales team for chemical luminescence products is being developed through a combination of internal selection and external recruitment [4] - The sales approach will continue to utilize a distributor model, with targeted marketing strategies based on market conditions and product performance [4] Vision and Market Position - The company aspires to become a global service provider for laboratory solutions, currently covering about 50% of hospital testing projects [4] - Plans to enter fields such as immunology, biochemistry, hematology, microbiology, POCT, and molecular diagnostics are underway to achieve comprehensive development in the IVD sector [4]